Abstract A029: Biomarker analysis of patients withMETΔex14 mutated non-small-cell lung cancer (NSCLC) treated with capmatinib in the GEOMETRY mono-1 study
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-19-a029
Abstract: In the phase 2 GEOMETRY mono-1 study, capmatinib has demonstrated clinically meaningful efficacy and a manageable safety profile in patients with advanced NSCLC harboring MET exon 14 skipping (METΔex14) mutations. Here, we report the biomarker… read more here.
Keywords: mono study; geometry mono; cancer; geometry ... See more keywords